Eupraxia Pharmaceuticals
EPRX
14 hedge funds and large institutions have $10.9M invested in Eupraxia Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 0 closing their positions.
27% more funds holding
Funds holding: 11 → 14 (+3)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.57% less ownership
Funds ownership: 6.05% → 5.48% (-0.57%)
51% less capital inflows, than outflows
Capital inflows: $719K | Capital outflows: $1.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$329K |
| 2 |
Ingalls & Snyder LLC
New York
|
+$143K |
| 3 |
JP Morgan Chase
New York
|
+$61.5K |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$57.6K |
| 5 |
Quadrature Capital
London,
United Kingdom
|
+$41.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Scotia Capital
Toronto,
Ontario, Canada
|
-$1M |
| 2 |
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$366K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$57.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$52.6K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$131 |
EPRX Hedge Fund Activity: Q2 2025 in Review
14 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q2 2025, worth a combined $10.9M — up 54% from $7.09M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EPRX positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $329K. The largest seller was Scotia Capital, cutting an estimated $1M.
- 14 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q2 2025, up from 11 in Q1 2025.
- Funds reported $10.9M of Eupraxia Pharmaceuticals stock for Q2 2025, up 54% quarter-over-quarter.
- 3 funds opened new Eupraxia Pharmaceuticals positions in Q2 2025 and 0 closed out, a net change of +3 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q2 2025 was Royal Bank of Canada, an estimated $329K added.
- The largest Eupraxia Pharmaceuticals seller in Q2 2025 was Scotia Capital, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2025.